Artificial Organs Market Size, Share, Trends, Report 2026 To 2035

Artificial Organs Market Size, Forecast Report 2026 To 2035

The global artificial organs market size was estimated at USD 28.71 billion in 2025 and is projected to surpass USD 63.31 billion by 2035; growing at a CAGR of 8.2% during the forecast period of 2026-2035. The transition from conventional mechanical replacement toward more responsive, biologically integrated, and patient-specific artificial organs is further expanding the market's long-term growth potential.

Report Highlights

• By region, North America dominated the artificial organs market with a 39.96% share in 2025 and is projected to grow at an 8.8% CAGR from 2026 to 2035, supported by advanced healthcare infrastructure, high healthcare expenditure, sophisticated medical technology adoption, and strong research and development capabilities. 
• By region, Europe was the second-largest and second-fastest-growing regional market, accounting for 27.86% in 2025 and projected to expand at an 8.6% CAGR from 2026 to 2035, owing to its established healthcare systems, aging population, advanced medical research ecosystem, and growing adoption of innovative organ-replacement technologies.
• By organ type, artificial kidney dominated the artificial organs market with a 45.00% share in 2025, owing to the sustained demand for renal replacement therapy, established treatment infrastructure, and the recurrent requirement for kidney-support systems.
• By organ type, artificial liver is projected to be the fastest-growing segment, registering a 28.6% CAGR from 2026 to 2035, driven by the rising need for advanced support for severe liver dysfunction and continued development of bioartificial, cell-based, filtration, and detoxification technologies.
• By fixation/mode of use, implantable artificial organs dominated the market with a 73.00% share in 2025, supported by their ability to provide continuous physiological support while reducing dependence on external equipment.
• By fixation/mode of use, externally worn/wearable artificial organs held the second-largest share of 17.00% in 2025, owing to advances in miniaturized sensors, portable power systems, wireless connectivity, and compact device architectures.
• By duration of use, permanent artificial organs accounted for the largest share of 40.00% in 2025, as patients with irreversible organ dysfunction require durable and dependable solutions capable of providing long-term replacement or support.
• By duration of use, long-term/chronic artificial organs represented the second-largest segment with a 35.00% share in 2025, supported by the growing need for prolonged organ assistance among patients experiencing chronic organ malfunction.
• By material, silicone dominated the artificial organs market with a 27.00% share in 2025, owing to its flexibility, durability, chemical stability, and established utilization across artificial-organ and medical-device applications.
• By material, polyurethane/other polymers held the second-largest share at 25.00% in 2025, driven by the ability to engineer polymer properties such as flexibility, elasticity, strength, durability, and resistance to environmental degradation for different artificial-organ applications.
• By technology, mechanical/fluidic technology dominated with a 38.00% market share in 2025, owing to its established role in pumping, filtering, directing, and regulating biological fluids across a wide range of artificial-organ systems.
• By technology, electronic/sensor-controlled technology held the second-largest share of 25.00% in 2025, supported by increasing integration of sensors and electronic controls that enable artificial organs to monitor physiological conditions and respond more precisely to patient requirements.
• By functional mechanism, mechanical artificial organs dominated with a 43.00% share in 2025, owing to the mature technological foundation and established use of mechanical mechanisms such as pumps and filters for replicating essential physiological functions.
• By functional mechanism, electronic/electromechanical artificial organs held the second-largest share of 27.00% in 2025, driven by the integration of sensors, processors, actuators, and control circuits that enable greater adaptability and responsiveness to changing body conditions.

What is Artificial Organs Market & How is it Expanding?

The global artificial organs market consists of a wide range of products and services including artificial organs (medical devices, engineered systems, and innovative solutions that are used to substitute, support, or mimic impaired and diseased body parts). This includes artificial kidneys, hearts, lungs, livers and pancreases, among others. Furthermore, the artificial organ market encompasses next-generation organ-replacement technologies based on mechanical, electronic, bioengineering, tissue engineering and regenerative concepts.

Rising demand for organ replacement, increased incidence of chronic and organ failure diseases coupled with their higher mortality rates, advancements in biomaterials used for the production of artificial organs, widespread adoption of miniaturized components and sensor-integrated devices and the increase in R&D investment on tissue-engineering and bioartificial organs are expected to be the key growth drivers of the Artificial Organs market.

Market Dynamics

Driver

Rising incidence of organ failure and chronic diseases

The increasing prevalence of chronic diseases and progressive organ failure is a major driver of the artificial organs market. Conditions such as chronic kidney disease, cardiovascular disorders, diabetes, liver disease, and other chronic illnesses can progressively impair vital organ functions, increasing the requirement for technologies capable of replacing or supporting those functions. The growing patient population requiring renal replacement therapy, cardiac support, and other forms of organ assistance creates a sustained clinical demand for artificial-organ technologies. This demand is further reinforced by the aging population, as older individuals have a higher incidence of chronic diseases and organ dysfunction.

Restraint

Shortage of donor organs and growing transplantation gap

There is also the on going short fall of donor organ to demand in general which is speeding up need for artificial organ technology. The supply and demand issue for donor organ still exists whereby patients continue to exceed actual organs, leaving them with extended delays on waiting lists, and the potential to decline while waiting to receive an organ.

Artificial organs are helping to fill the void for replacement and supporting the need where a compatible human donor is not readily available. The likes of artificial kidneys, artificial hearts and also ventricular assist devices together with the new and more innovative bioartificial organs are becoming more viable and are providing alternative and transitional solutions for patients in need.

Opportunity

Technological advancements in artificial-organ systems

Rapid advances in biomaterials, miniaturized electronics, sensors, microfluidics, tissue engineering, and regenerative medicine are improving the performance and potential applications of artificial organs. Modern systems are increasingly designed to provide more precise physiological control, improved biocompatibility, greater durability, and better patient mobility compared with earlier-generation devices. Sensor-controlled technologies can monitor physiological parameters and adjust device performance, while advanced materials can reduce biological complications and improve long-term functionality. At the same time, developments in tissue engineering, cell-based technologies, and 3D bioprinting are moving the industry beyond conventional mechanical replacement toward biologically integrated organs.

Segmental Insights

Organ Type Insights

Artificial kidney dominated the artificial organs market, accounting for 45.00% of the market in 2025. The segment is projected to maintain its leading position through 2035, representing a 5.5% CAGR during 2026–2035. The dominance of kidney-support systems is owing to its high demand and sustained requirement by the individuals with end-stage kidney damage that requires artificial replacement therapy.

Kidney support systems have relatively large base of established clinical application owing to vast treatment facilities, specialized health infrastructure, large treatment base, lifelong need for artificial kidney for renal replacement therapy, consistent requirement owing to the recurrent treatment for kidney diseases and advancement and innovation in the filtration, ease to use, biocompatibility and design to offer better efficiency in the replacement systems.

Artificial liver is projected to be the fastest-growing segment, registering an estimated 28.6% CAGR from 2026 to 2035. Its market share is expected to increase sharply from 2.10% in 2025 to 10.00% by 2035, while its market value is projected to rise from 0.66 in 2026 to 6.33 by 2035. The rapid expansion of artificial liver technologies reflects the significant unmet need for solutions capable of supporting patients with severe liver dysfunction and providing temporary or sustained assistance to critical liver functions.

Artificial-liver systems can potentially serve as a bridge for patients awaiting transplantation or as supportive technologies during severe liver injury. The segment is also benefiting from advances in bioartificial systems, cell-based approaches, filtration and detoxification technologies, and the broader development of organ-support platforms capable of replicating complex biological functions.

Fixation/Mode of Use Insights

By fixation/mode of use, implantable artificial organs held a dominant share with 73.00% market share in 2025. Growing demand for continuous support of organs directly within the patient body makes the market implantable artificial organs to a leader. Implantable artificial organs help in reducing the need for external equipment which the patients required and facilitates continuous support of physiological function of the organs and the trend plays significant role especially in chronic applications.

Miniaturization of mechanical parts, sensor and control electronic system, advanced biocompatible materials and improved surgical procedures are few factors attributing towards an increased utilization of implantable artificial organs over the long-term use.

Artificial Organs Market Share, By Fixation/Mode of Use, 2025 (%)

Externally worn/wearable artificial organs constituted the second-largest mode-of-use segment, with a 17.00% share in 2025. Wearable systems provide an important alternative when full implantation is technically challenging, clinically unsuitable, or still under development. Their development is being supported by miniaturized sensors, portable power systems, wireless connectivity, compact mechanical components, and improved monitoring capabilities. Wearable artificial-organ technologies can also serve as transitional systems between conventional external treatment and fully implantable solutions.

Duration of Use Insights

Permanent artificial organs dominated the duration-of-use segment, accounting for 40% of the market in 2025. A dominant position held by permanent artificial organs may be attributed to the long-term use, i.e., replacement or continuation of a functioning unit in situation where natural organ functions cannot be sufficiently restored. Implantable devices in the segment must be sufficiently durable, bio-compatible, dependable, and resist biological deterioration since they may remain functioning over long durations.

The factors that could stimulate growth of this segment include continued development of biomaterials, improved surface modifications, miniature component technologies, power management, and device tracking.

Artificial Organs Market Share, By Duration of Use, 2025 (%)

Long-term/chronic artificial organs represented the second-largest duration category, with a 35% share in 2025. Long-term/chronic solutions designed for patients whose life is prolonged by a prolonged artificial organ support were projected to grow due to the increasing number of patients suffering from chronic organ malfunction and require assistance throughout their life.

Material Insights

The leading material applied in the artificial organ market was silicone during 2025 which accounted for 27.00% and it is forecast that it will hold 26.00% during the years up to 2035. Silicone has been used across most device applications such as the applications and devices such as mechanical-heart and skin patches due to its characteristics including; good flexibility, durability, chemical stability and is currently widespread across device applications of artificial organs in the world.

Polyurethane/other polymers represented the second-largest material segment, accounting for 25.00% in 2025 and projected to account for 23.00% by 2035. Polymer-based materials are widely relevant to artificial-organ development because their mechanical and chemical characteristics can be engineered for specific applications.

Depending on the formulation, polymers can provide flexibility, elasticity, strength, durability, and resistance to environmental degradation. Their versatility enables their use in different components and device architectures. The relatively small difference between silicone and polyurethane/other polymers highlights the competitive nature of the polymer-material landscape within artificial-organ manufacturing.

Technology Insights

Mechanical/fluidic technology, held the highest market share in 2025 with 38.00%. Mechanical and fluidic technologies continue to play a significant role in artificial organ development because many organ functions are derived from a need to appropriately direct, filter, pump or otherwise regulate the flow of biological fluids. Flow pathways and control systems, pressure managing and control systems, pumps, filters, and valves make up the basic engineering foundation for most artificial organs. Generally accepted engineering practices applied toward mechanical and fluidic technologies, as well as developed manufacturing capabilities, help ensure these areas represent large portions of the technology market share.

Artificial Organs Market Share, By Technology, 2025 (%)

Electronic/sensor-controlled technology was the second-largest technology segment, accounting for 25.00% of the market in 2025. The segment is gaining importance as artificial organs become increasingly responsive and data-driven. Sensors can monitor physiological parameters, while electronic control systems can adjust device operation according to changing patient requirements. This integration can improve the precision and responsiveness of artificial organs and reduce dependence on fixed operating parameters.

Functional Mechanism Insights

Mechanical artificial organs dominated the functional-mechanism segment, accounting for 43% of the market in 2025. The dominance of mechanical artificial organs is attributed to the existing understanding of the integration of mechanical principles to carry out the physiological process.

Hence, mechanical artificial organs have use in cases where the bodily process can be simulated using the mechanisms like pump and filter. Mechanical artificial organs are readily available, and a mature technology background is responsible for the established infrastructure of the market.

Artificial Organs Market Share, By Functional Mechanism, 2025 (%)

Electronic/electromechanical artificial organs section held the second position in the functional-mechanism segment for the artificial organs market in 2025, and has a market share of 27%. These are designed by integrating the mechanical functions of the artificial organ with electronic components like sensors, processors, actuating devices, and control circuits. With the advancement in technologies, modern artificial organs require more advanced features like adaptability and the ability to react with the body conditions. 

Regional Insights

What Made North America Dominate the Artificial Organs Market in 2025?

North America dominated the global artificial organs market, accounting for 39.96% of the market in 2025, representing an 8.8% CAGR. North America's leadership is supported by advanced healthcare infrastructure, high adoption of sophisticated medical technologies, strong research and development capabilities, and the availability of specialized clinical facilities.

The region also benefits from an established ecosystem connecting medical researchers, healthcare institutions, technology developers, and medical-device companies, facilitating the translation of artificial-organ innovations into clinical applications. High healthcare expenditure and access to advanced treatment technologies further strengthen the region's position.

Projection of Europe in Artificial Organs Market

Europe generated revenue of 27.86% in the global artificial organs market in the year 2025, positioning it as the second biggest regional market and is anticipated to expand at a CAGR of 8.6% from 2026 to 2035. Regional market is expected to augment from US$8.71 billion in 2026 to US$18.36 billion by the end of 2035 whereas its market share is estimated to go up to 29.00% by 2035.

Favorable reasons contributing to the robust regional growth includes the well-established healthcare structure, mounting adoption of sophisticated medical technologies along with well-advanced research abilities over medical-devices and biotechnology applications.

Also, presence of some specialized hospitals, top-notch treatment facilities, robust reimbursement schemes, and advanced medical device eco-system contribute to growing commercial potential for artificial organ technologies in the region.

How are Asian Countries Booming in the Artificial Organs Market?

Asia-Pacific is a strategic high potential region market that is expected to comprise 22.41% in 2025 and grow with a CAGR of 7.4% for the forecast period of 2026-2035. The Asia-Pacific market size is expected to increase from US$7.01 million in 2026 to US$13.30 million in 2035.

The region is propelled by extensive patient population, growth in healthcare infrastructure, increment in healthcare spending, and enhancing access to novel medical technologies. Moreover, growing awareness regarding advanced organ-support and replacement therapies is creating avenues for companies manufacturing and supplying the devices.

Top Initiatives to Support the Artificial Organs Market:

Artificial Organs Market Competitive Landscape

• Medtronic plc - One of largest medical-device manufacturers, they take part in artificial-organ technologies via cardiac as well as renal support technologies and other broader medical devices.
• Abbott Laboratories - Involved in the cardiovascular technologies by having mechanical circulatory support capacities along with being an established player with the presence on devices that can support heart failure functioning.
• Baxter International Inc. - Key contributor on the renal care devices by having innovative solutions in dialysis system and its linked technologies to be employed by artificial and extracorporeal organ-function markets. Baxter International Inc.
• Fresenius Medical Care AG & Co. KGaA - An important participant in the renal replacement therapies through hemodialysis machine, dialysis solutions, and others renal caring technologies.
• Terumo Corporation - Another key contributor to the artificial-organ ecosystem through their technologies in cardiovascular support machines and products in blood management as well as dialysis technologies.
• SynCardia Systems, LLC - A more niche market players where their main product on artificial organ functioning falls in the category of total heart devices. Being the manufacturer of a total artificial heart they represent the established firms focusing in using mechanics to replace heart functions.

Recent News, Product Launches & Breakthroughs

• May 2025 –BiVACOR announced that its titanium Total Artificial Heart received the U.S. FDA's Breakthrough Device Designation in May 2025. The designation represents an important regulatory milestone for the company's magnetically levitated artificial-heart technology and supports its continued clinical development.
• August 2025 – BiVACOR announced in August 2025 that its Total Artificial Heart had been accepted into the FDA's Total Product Life Cycle Advisory Program, strengthening the company's regulatory engagement as it advances development of the device. The milestone followed the device's earlier Breakthrough Device Designation and clinical development activities.

Segments Covered

By Organ Type

• Artificial Kidney
• Artificial Heart
• Artificial Lung
• Artificial Liver
• Artificial Pancreas
• Others

By Fixation/Mode of Use

• Implantable
• Externally Worn / Wearable
• Extracorporeal

By Duration of Use 

• Temporary / Short-Term
• Long-Term / Chronic
• Permanent

By Material

• Silicone
• Polyurethane / Other Polymers
• Metals / Metal Alloys
• Ceramics / Glass
• Biomaterials
• Composite / Hybrid Materials
• Other Materials

By Technology 

• Mechanical / Fluidic Technology
• Electronic / Sensor-Controlled Technology
• Microfluidic Technology
• Bioengineering / Cell-Based Technology
• Tissue Engineering / Regenerative Technology
• 3D Bioprinting
• Hybrid / Other Emerging Technologies

By Functional Mechanism

• Mechanical Artificial Organs
• Electronic / Electromechanical Artificial Organs
• Bioartificial Organs
• Tissue-Engineered Organs
• Hybrid / Integrated Artificial Organs

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa